Comparison of Exacerbation Risk and Health Outcomes in Maintenance Treatment naïve Chronic Obstructive Pulmonary Disease (COPD) Patients Using Stiolto Versus Trelegy, a Real-World Study
Latest Information Update: 25 Oct 2023
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 11 Jan 2022 Status changed from active, no longer recruiting to completed.
- 04 Jan 2022 New trial record